MP-2026-VTX-JP · Vantrexa · Oncology / Non-small cell lung cancer
PRD planning workflow. The current state is highlighted.
Local adaptation of the global plan. PMDA approval expected Q4 2026; focus on pathology testing infrastructure and JSMO engagement.
Japanese subgroup safety data
No project yet
SO-VTX-JP-01
Japanese KOL advocacy drives hospital formulary decisions.
Linked initiatives (1)
Planned versus delivered, and activity versus outcome for this product.
Initiatives completed
0 / 1
1 at risk or blocked
Milestones
1 / 3 done
0 on time · 1 late · 1 overdue · 1 upcoming
Budget consumed
58%
$640k of $1.1M · initiatives $172k of $310k
Activity → outcome
114 → 33 → 2
Engagements → insights → actions for this product
Activity counts (engagements) are not outcomes. Insights and actions are shown alongside so that activity is read against what it produced. Budget figures for the plan come from Finance; initiative spend is entered by initiative owners.
Newest first. Each version records who changed the plan and what changed.
24 Feb 2026 · v2
Approved with adjusted JSMO congress budget.
By Dr. Priya Raman · current version
02 Feb 2026 · v1
Draft aligned with global v3.
By Dr. Kenji Watanabe
| Dependency | Dependent | Depends on | Type | Due | Status | Impact if delayed |
|---|---|---|---|---|---|---|
| DEP-0002 | Japan Tier 1 engagement | Second Japan MSL hire (Decision) | Internal | 26 Sept 2026 | At risk | Coverage below target at PMDA approval |
| Initiative | Type | Objective | Owner | Priority | Status | Progress | End |
|---|---|---|---|---|---|---|---|
| Japan Tier 1 KOL engagement and JSMO presence | Field medical campaign | SO-VTX-JP-01 | KWDr. Kenji Watanabe | High | At risk | 48% | 20 Dec 2026 |
No audit events for this record
Audit events are written when the record is created, changed, approved, signed or exported.